Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Receivables (2016 - 2026)

Perspective Therapeutics' Receivables history spans 16 years, with the latest figure at $58000.0 for Q1 2026.

  • On a quarterly basis, Receivables fell 25.64% to $58000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $58000.0, a 25.64% decrease, with the full-year FY2025 number at $16000.0, down 97.35% from a year prior.
  • Receivables hit $58000.0 in Q1 2026 for Perspective Therapeutics, up from $16000.0 in the prior quarter.
  • Over the last five years, Receivables for CATX hit a ceiling of $2.1 million in Q1 2022 and a floor of $16000.0 in Q4 2025.
  • Historically, Receivables has averaged $837823.5 across 5 years, with a median of $999000.0 in 2024.
  • The widest YoY moves for Receivables: up 58.45% in 2025, down 97.35% in 2025.
  • Tracing CATX's Receivables over 5 years: stood at $1.4 million in 2022, then decreased by 13.92% to $1.2 million in 2023, then tumbled by 48.68% to $603000.0 in 2024, then tumbled by 97.35% to $16000.0 in 2025, then surged by 262.5% to $58000.0 in 2026.
  • Business Quant data shows Receivables for CATX at $58000.0 in Q1 2026, $16000.0 in Q4 2025, and $179000.0 in Q3 2025.